Combinatorial expression of cell cycle regulators is more suitable for immortalization than oncogenic methods in dermal papilla cells.

Cell Biology Stem Cell Research Technical Aspects of Cell Biology

Journal

iScience
ISSN: 2589-0042
Titre abrégé: iScience
Pays: United States
ID NLM: 101724038

Informations de publication

Date de publication:
22 Jan 2021
Historique:
received: 29 05 2020
revised: 05 11 2020
accepted: 08 12 2020
entrez: 13 1 2021
pubmed: 14 1 2021
medline: 14 1 2021
Statut: epublish

Résumé

The immortalized cell is an essential research tool that uses robust growth properties for the functional investigation of gene products. Immortalized mammalian cells have mainly been established using three methods: expression of simian vacuolating virus 40 T antigen (the SV40 method); human papilloma virus-derived oncoprotein E6/E7 (the E6/E7 method); or combinatorial expression of R24C mutant cyclin-dependent kinase 4, cyclin D1, and telomerase reverse transcriptase (the K4DT method). However, it is unclear as to which method is optimal for an

Identifiants

pubmed: 33437932
doi: 10.1016/j.isci.2020.101929
pii: S2589-0042(20)31126-3
pmc: PMC7788094
doi:

Banques de données

figshare
['10.6084/m9.figshare.12197691.v2']

Types de publication

Journal Article

Langues

eng

Pagination

101929

Informations de copyright

© 2020 The Author(s).

Déclaration de conflit d'intérêts

The authors declare no conflict of interests.

Références

Virology. 1984 Sep;137(2):414-21
pubmed: 6091337
J Biotechnol. 2014 Apr 20;176:50-7
pubmed: 24589663
Front Cell Dev Biol. 2020 Mar 18;8:157
pubmed: 32269992
Virus Res. 2002 Nov;89(2):213-28
pubmed: 12445661
Oncogene. 1998 Jul 16;17(2):199-205
pubmed: 9674704
PLoS One. 2019 Aug 26;14(8):e0221364
pubmed: 31449544
EMBO J. 1989 Dec 20;8(13):4099-105
pubmed: 2556261
Front Genet. 2019 Jul 16;10:587
pubmed: 31379915
Nat Rev Cancer. 2002 May;2(5):342-50
pubmed: 12044010
EMBO J. 1989 Dec 1;8(12):3905-10
pubmed: 2555178
Oncogene. 2005 Nov 21;24(52):7729-45
pubmed: 16299533
J Invest Dermatol. 2008 Feb;128(2):262-9
pubmed: 17657240
Cell Biosci. 2019 Jan 5;9:7
pubmed: 30627420
Exp Cell Res. 1965 Mar;37:614-36
pubmed: 14315085
J Cell Biochem. 2015 Feb;116(2):205-11
pubmed: 25187009
Obstet Gynecol. 1971 Dec;38(6):945-9
pubmed: 4942173
Nature. 1992 Jul 2;358(6381):15-6
pubmed: 1614522
Biosci Biotechnol Biochem. 2012;76(7):1372-7
pubmed: 22785463
BMC Res Notes. 2019 Mar 13;12(1):133
pubmed: 30867032
J Biol Chem. 2001 Sep 7;276(36):33533-9
pubmed: 11438528
Cell. 1990 Dec 21;63(6):1129-36
pubmed: 2175676
Gene Ther. 2011 Sep;18(9):857-66
pubmed: 21490680
Methods Mol Biol. 2001;165:185-99
pubmed: 11217385
Cell Death Differ. 2006 Jun;13(6):1017-26
pubmed: 16557268
Sci Data. 2019 Feb 26;6:190034
pubmed: 30806635

Auteurs

Tomokazu Fukuda (T)

Graduate School of Science and Engineering, Iwate University, 4-3-5 Ueda, Morioka, Iwate, 020-8551 Japan.

Kai Furuya (K)

Graduate School of Science and Engineering, Iwate University, 4-3-5 Ueda, Morioka, Iwate, 020-8551 Japan.

Kouhei Takahashi (K)

Graduate School of Science and Engineering, Iwate University, 4-3-5 Ueda, Morioka, Iwate, 020-8551 Japan.

Ai Orimoto (A)

Graduate School of Science and Engineering, Iwate University, 4-3-5 Ueda, Morioka, Iwate, 020-8551 Japan.

Eriko Sugano (E)

Graduate School of Science and Engineering, Iwate University, 4-3-5 Ueda, Morioka, Iwate, 020-8551 Japan.

Hiroshi Tomita (H)

Graduate School of Science and Engineering, Iwate University, 4-3-5 Ueda, Morioka, Iwate, 020-8551 Japan.

Sayo Kashiwagi (S)

Rohto Pharmaceutical Co., Ltd., Basic Research Development Division, 6-5-4 Kunimidai, Kizugawa, Kyoto, 619-0216, Japan.

Tohru Kiyono (T)

Exploratory Oncology Research & Clinical Trial Center, National Cancer Center, 6-5-1 Kashiwanoha, Kashiwa-city, Chiba, 277-8577, Japan.

Tsuyoshi Ishii (T)

Rohto Pharmaceutical Co., Ltd., Basic Research Development Division, 6-5-4 Kunimidai, Kizugawa, Kyoto, 619-0216, Japan.

Classifications MeSH